An observational study published in PLOS Global Mental Health looks at screentime, sleep and depression in adolescents. Prof Ben Carter, Professor of Medical Statistics, Institute of Psychiatry, ...

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the ...

Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...

Aerin Medical’s 3-year study confirms VivAer® provides lasting relief for nasal obstruction (NAO), improving airflow, sleep, ...

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

Given sleep’s profound impact on well-being, unexplained daytime fatigue and disrupted sleep patterns necessitate a ...

Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Axsome Therapeutics, Inc. has announced the topline results of the Paradigm Phase 3 proof-of-concept trial of Solriamfetol in major depressive disorder (MDD) with and without excessive daytime ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Shares of GRI Bio Inc. (NASDAQ:GRI) were trading at $6.28, up $3.08, or 96%, after the firm reported interim safety results from the ongoing phase IIa study testing GRI-0621 for idiopathic pulmonary ...

Shares of biopharmaceutical company Axsome Therapeutics ( AXSM -6.29%) had declined 6% at 11 a.m. ET today. The slump comes ...